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Eﬀ ect of high-dose simvastatin on brain atrophy and 
disability in secondary progressive multiple sclerosis 
(MS-STAT): a randomised, placebo-controlled, phase 2 trial
Jeremy Chataway, Nadine Schuerer, Ali Alsanousi, Dennis Chan, David MacManus, Kelvin Hunter, Val Anderson, Charles R M Bangham, 
Shona Clegg, Casper Nielsen, Nick C Fox, David Wilkie, Jennifer M Nicholas, Virginia L Calder, John Greenwood, Chris Frost, Richard Nicholas
Summary
Background Secondary progressive multiple sclerosis, for which no satisfactory treatment presently exists, accounts 
for most of the disability in patients with multiple sclerosis. Simvastatin, which is widely used for treatment of 
vascular disease, with its excellent safety proﬁ le, has immunomodulatory and neuroprotective properties that could 
make it an appealing candidate drug for patients with secondary progressive multiple sclerosis.
Methods We undertook a double-blind, controlled trial between Jan 28, 2008, and Nov 4, 2011, at three neuroscience 
centres in the UK. Patients aged 18–65 years with secondary progressive multiple sclerosis were randomly assigned 
(1:1), by a centralised web-based service with a block size of eight, to receive either 80 mg of simvastatin or placebo. 
Patients, treating physicians, and outcome assessors were masked to treatment allocation. The primary outcome was 
the annualised rate of whole-brain atrophy measured from serial volumetric MRI. Analyses were by intention to treat 
and per protocol. This trial is registered with ClinicalTrials.gov, number NCT00647348.
Findings 140 participants were randomly assigned to receive either simvastatin (n=70) or placebo (n=70). The mean 
annualised atrophy rate was signiﬁ cantly lower in patients in the simvastatin group (0·288% per year [SD 0·521]) 
than in those in the placebo group (0·584% per year [0·498]). The adjusted diﬀ erence in atrophy rate between groups 
was −0·254% per year (95% CI −0·422 to −0·087; p=0·003); a 43% reduction in annualised rate. Simvastatin was well 
tolerated, with no diﬀ erences between the placebo and simvastatin groups in proportions of participants who had 
serious adverse events (14 [20%] vs nine [13%]).
Interpretation High-dose simvastatin reduced the annualised rate of whole-brain atrophy compared with placebo, and 
was well tolerated and safe. These results support the advancement of this treatment to phase 3 testing.
Funding The Moulton Foundation [charity number 1109891], Berkeley Foundation [268369], the Multiple Sclerosis 
Trials Collaboration [1113598], the Rosetrees Trust [298582] and a personal contribution from A Pidgley, UK 
National Institute of Health Research (NIHR) University College London Hospitals/UCL Biomedical Research 
Centres funding scheme.
Copyright © Chataway et al. Open Access article distributed under the terms of CC BY.
Introduction
Multiple sclerosis is a major cause of disability, particularly 
in young adults in temperate climates. Despite much 
success with drugs that substantially reduce relapse 
frequency during the initial inﬂ ammatory, relapsing-
remitting phase, more than half of patients eventually 
develop non-relapsing, secondary progressive multiple 
sclerosis one to two decades after the onset of relapsing-
remitting multiple sclerosis. This relentless accumulation 
of neurological deﬁ cit and increasing brain atrophy is 
thought to be driven by neuroaxonal loss.1 Although 
several symptomatic treatments are available, progression 
in secondary progressive multiple sclerosis is presently 
intractable. Immunomodulatory strategies derived from 
relapsing-remitting multiple sclerosis have not proven 
eﬀ ective when extended into secondary progressive 
multiple sclerosis (eg, cyclophosphamide,2 β-interferon,3,4 
myelin-basic protein5). Direct neuroprotection strategies 
(eg, lamotrigine,6 tetrahydrocannabinol7) have also failed.8 
The crucial and as yet unmet challenge is to ﬁ nd eﬀ ective 
and well-tolerated treatments for secondary pro gressive 
multiple sclerosis.
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase 
inhibitors (statins), which inhibit the catalytic conversion 
of HMG-CoA to mevalonate, are extensively used and 
well tolerated in the treatment of primary 
hyperlipidaemia, and for secondary prevention of 
myocardial and cerebral ischaemia. Clinical beneﬁ ts 
noted in these disorders are due to both direct cholesterol 
lowering, and to cholesterol-independent eﬀ ects. In 
murine models, statins inhibit MHC class II-restricted 
antigen presentation, downregulate T-cell activation and 
proliferation and induce a shift from a pro-inﬂ ammatory 
Th1 to a Th2 phenotype.9 Statins also block adhesion 
molecule expression and inhibit leucocyte migration 
through the blood-brain barrier, supporting their 
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potential use in early multiple sclerosis.10–12 However, 
because statins also have cell protective properties13 and 
improve cerebrovascular haemo dynamics,14 they could be 
used in patients with later stage multiple sclerosis in 
whom vascular15 and brain parenchymal cell dysfunction 
take place.13
Initial clinical studies of patients with early stage 
multiple sclerosis with high-dose (80 mg) simvastatin 
showed a signiﬁ cant reduction in lesion activity.16 
Subsequent randomised controlled trials of simvastatin17,18 
and atorvastatin19–21 as add-on therapy to β-interferon in 
patients with relapsing-remitting multiple sclerosis have 
yielded conﬂ icting results, although they were hampered 
by insuﬃ  cient power. We undertook a randomised 
controlled trial of high-dose simvastatin to assess the role 
of statins further in secondary progressive multiple 
sclerosis.
Methods
Study design and participants
We undertook this investigator-led, double blind, placebo-
controlled, parallel-group, randomised trial between 
Jan 28, 2008, and Nov 4, 2011 at three neuroscience centres 
in London and southeast England. 
To be eligible for the study, patients had to be aged 
18–65 years, have an Expanded Disability Severity Scale 
(EDSS)22 score of 4·0–6·5 and fulﬁ l the revised McDonald 
criteria for multiple sclerosis,23 and at randomisation 
have entered the secondary progressive stage.24 The 
deﬁ nition of secondary progressive stage was in keeping 
with that used in other secondary progressive multiple 
sclerosis trials.6 Steady progression rather than relapse 
had to be the major cause of increasing disability in the 
preceding 2 years, conﬁ rmed on the basis of either an 
increase of at least one point on the EDSS or clinically 
documented increasing disability. Patients were ineligible 
if they had primary progressive multiple sclerosis; had a 
relapse or had been treated with corticosteroids within 
3 months of screening; or used immunosuppressants 
(eg, azathioprine, methotrexate, ciclosporin) or disease 
modifying treatments (avonex, rebif, betaferon, glati-
ramer acetate) within the previous 6 months. Detailed 
inclusion and exclusion criteria are available elsewhere.25 
Patients were seen at months 1, 6, 12, and 24 with 
telephone follow-up at months 3 and 18. 
The study was done in accordance with Good Clinical 
Practice26 and the Declaration of Helsinki.27 The protocol 
was approved by each study site’s institutional review 
board, and all patients gave informed consent before 
entering the study.
Randomisation and masking
Patients were randomised in a 1:1 ratio to receive 
simvastatin 80 mg, or matching placebo drug (after a 
ﬁ rst month at 40 mg a day), for 24 months. Randomisation 
was done by a centralised web-based service, with block 
size of eight, and minimisation28 on the following 
variables: age (<45, ≥45 years old); sex; EDSS (4–5·5, 
6·0–6·5); centre; and assessing physician. Patients, 
treating physicians, and outcome assessors (including 
MRI scan analysts) were masked to treatment allocation. 
To ensure full masking, both a treating and an 
independent qualiﬁ ed examining neurologist were 
involved in the trial.
Procedures
The predeﬁ ned primary endpoint was the rate of whole-
brain atrophy per year, measured as relative change in 
brain volume by K-means normalisation brain boundary 
shift integral (BSI),29,30 based on each pair of volumetric 
T1 MRI scans between baseline, 12 months, and 
25 months. BSI, like structural image evaluation using 
normalisation of atrophy (SIENA) is a well-validated and 
established registration-based, semi-automated, direct 
measure of volume change that has robust performance 
characteristics.31–33 The volumetric scan was acquired 
twice at baseline, with the best-quality scan chosen for 
analysis on the basis of expert visual rating of motion and 
artifact. Scan acquisition sequence parameters were also 
reviewed to ensure longitudinal consistency. The ﬁ nal 
scan was 1 month after last medication to minimise any 
potential eﬀ ect of changes in artifactual volume, such as 
pseudoatrophy (a short term reduction in brain volume 
due to an anti-inﬂ ammatory eﬀ ect);34 thus, both the 
baseline and end-of study scans were oﬀ -medication. The 
MRI secondary endpoint, assessed at 12 months and 
25 months was the number of new and enlarging T2 
brain lesions (for acquisition parameters see appendix).Figure 1: Patient ﬂ ow diagram
408 patients assessed for eligibility 
268 excluded  
107 did not meet 
inclusion criteria 
96 declined to participate 
65 trial recruitment closed 140 randomised 
70 allocated to simvastatin  
3 lost to follow-up by 24 months  
1 unable to contact  
1 declined follow-up  
1 wanted to discontinue medication  
15 completed 24 month follow-up but were
less than 90% compliant:
4 were 0% compliant  
6 were 1–50% compliant  
5 were 51–89% compliant  
66 analysed for primary outcome 
 4 excluded from analysis  
 3 did not attend MRI at follow-up  
 1 MRI failed quality control checks
70 allocated to placebo  
6 lost to follow-up by 24 months  
1 unable to contact  
3 declined follow-up  
1 had ill health (sub-arachnoid 
haemorrhage)   
1 had side-eﬀects from the medication 
15 completed 24 month follow-up but were
less than 90% compliant:
3 were 0% compliant 
9 were 1–50% compliant 
3 were 51–89% compliant  
64 analysed for primary outcome 
6 excluded from analysis 
6 did not attend MRI at follow-up
See Online for appendix
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Clinical outcomes assessed at baseline, 12 months, and 
24 months were EDSS,22 multiple sclerosis func tional 
composite scale (MSFC),35 multiple sclerosis impact 
scale-29 (MSIS-29)36 version 2, and relapse frequency. 
The MSFC Z score was normalised with the study 
baseline scores. Choles terol levels were taken at baseline 
and 24 months.
We investigated phenotypic markers with whole blood 
specimens collected at baseline, 6, 12, and 24 months. 
Intracellular cytokine expression was examined in CD3+ 
T cells for IFN-γ, IL-4, and IL-17 as markers of Th/Tc1, 
Th/Tc2, and Th/Tc17 T-cell populations, respectively. 
Intracellular cytokine (IL-4, IFN-γ, IL-10, IL-17) expression 
on unstimulated T cells and cells stimulated with 
50 ng per mL of Phorbol 12-myristate 13-acetate and 
1 μg per mL ionomycin was done as previously described 
(appendix).37 Coexpression of CD4+ and intracellular 
expression of FoxP3 and IL-10 were examined as markers 
of regulatory T cells.
Statistical analysis
The sample size was chosen to give the trial 90% 
statistical power (with a conventional two-sided sig-
niﬁ cance level of 5%) to detect a diﬀ erence of 0·25% a 
year in whole-brain atrophy between the groups assum-
ing a mean atrophy rate in the placebo group of 0·6% a 
year and a standard deviation of 0·4% a year. With these 
assumptions 54 patients would be needed in each 
treatment group: in anticipation of dropouts and in-
complete follow-up this was increased to 70 patients per 
group. Analysis of all imaging and clinical outcomes 
were prespeciﬁ ed in a statistical analysis plan. Primary 
analyses were by intention to treat. A secondary analysis 
was undertaken using a per-protocol dataset, which 
comprised patients who complied with treatment and 
completed follow-up to 25 months. Participants were 
considered compliant with treatment if they reported 
taking, on average, at least 90% of their drug at a dose 
of 80 mg. Compliance was assessed by examination of 
the self-reported proportion of capsules taken in the 
month before the 6, 12, 18, and 24 month assessments. 
All analyses were done with STATA (version 12.1).
BSI-derived changes in whole-brain volume were 
converted into a percentage of the baseline whole-brain 
volume for each available scan interval giving up to 
three BSI values per participant (change between 
0–12 months, 12–25 months, and 0–25 months). A 
positive value for percentage change shows a decrease 
in brain volume. We compared mean rates of atrophy 
in the two treatment groups with the family of linear 
mixed models developed for the analysis of repeated 
measures of direct change.38 These models allow 
Placebo (n=70) Simvastatin (n=70)
n (%) Mean (SD) Median (range) n (%) Mean (SD) Median (range)
Women 48 (69%) ·· ·· 49 (70%) ·· ··
Ethnic origin
White 63 (90%) ·· ·· 69 (99%) ·· ··
Black 3 (4%) ·· ·· 0 (0%) ·· ··
Asian 1 (1%) ·· ·· 1 (1%) ·· ··
Other 3 (4%) ·· ·· 0 (0%) ·· ··
Relapse in past 12 months 12 (17%) ·· ·· 7 (10%) ·· ··
Relapse in past 24 months 18 (26%) ·· ·· 8 (11%) ·· ··
Age (years) 70 51·1 (6·8) 51·5 (36·5 to 64·6) 70 51·5 (7·0) 51·9 (34·8 to 64·6)
Multiple sclerosis duration 
(years)
70 20·3 (8·8) 18·8 (4·2 to 39·6) 70 22·1 (8·3) 21·8 (4·7 to 39·8)
SPMS duration (years) 70 7·1 (4·8) 5·3 (1·6 to 22·6) 70 7·3 (5·6) 5·4 (2·1 to 25·0)
Total cholesterol (mmol/L) 67 5·62 (0·87) 5·6 (3·80 to 7·40) 68 5·52 (1·09) 5·45 (3·70 to 8·90)
EDSS 70 5·87 (0·78) 6 (4 to 7)* 70 5·76 (0·84) 6 (4 to 6·5)
MSFC Z score 64 −0·29 (1·48) −0·06 (−6·66 to 1·24) 64 −0·03 (0·92) 0·00 (−5·33 to 1·37)
Paced auditory serial addition test 67 33·7 (16·1) 32 (0 to 59) 67 34·8 (13·8) 34 (0 to 57)
25ft walk average speed (ft per s) 68 1·50 (0·87) 1·38 (0·14 to 3·47) 66 1·67 (0·91) 1·58 (0·14 to 3·85)
Nine hole peg test (speed per s†) 69 0·033 (0·010) 0·035 (0·001 to 0·053) 67 0·034 (0·009) 0·034 (0·001 to 0·054)
MSIS-29 66 70·0 (14·5) 67·0 (34·0 to 102·3) 69 70·2 (14·0) 72·0 (38·5 to 107·0)
MSIS-29 physical 66 51·2 (10·4) 49·7 (25·0 to 72·6) 69 51·4 (10·6) 53·7 (29·5 to 79·0)
MSIS-29 psychological 66 18·8 (5·7) 19·0 (9·0 to 36·0) 69 18·9 (5·2) 18·0 (9·0 to 33·0)
Whole-brain volume (mL) 70 1098 (124) 1095 (881 to 1432) 70 1104 (118) 1106 (891 to 1474)
MSIS-29 range might take fractional values when a score for a missing item was imputed as the mean score of the completed items in the scale. SPMS=secondary progressive 
multiple sclerosis. EDSS=Kurtzke expanded disability status scale. MSFC=multiple sclerosis functional composite. MSIS=multiple sclerosis impact scale. *One patient changed from 
6·5 to 7·0 between screening and randomisation. †Speed of pegs placed.
 Table 1: Baseline characteristics
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simultaneous analysis of the changes over the three 
time intervals, appropriately allowing for the correlation 
between these points. Therefore all available atrophy 
measures were included in this analysis, with 
participants included in the analysis if they have at least 
one BSI measure of atrophy. 
An interaction between treatment group and time was 
included in the model as were other interactions between 
time and the minimisation variables and MRI site. The 
treatment eﬀ ect therefore represents the diﬀ erence 
between the treatment and placebo group in mean annual 
percentage change in whole-brain volume adjusted for 
minimisation variables and MRI site. Analysis of repeated 
measures with a properly speciﬁ ed linear mixed model 
including all follow-up data is more robust to dropouts 
than a complete case analysis. Speciﬁ cally, the estimated 
treatment eﬀ ect is unbiased under the missing-at-random 
assumption rather than the more stringent com pletely-
missing-at-random assumption, which is necessary for a 
complete case analysis to be unbiased.39 We judged that 
because whole-brain atrophy is the primary outcome 
variable in this trial, the additional statistical complexity 
introduced by using this approach was justiﬁ ed. However, 
we also report results from a simple comparison of rates 
of change over 25 months (adjusting for minimisation 
variables and site).
For EDSS, MSFC and subscales, and MSIS-29 and 
subscales, mean score at 24 months was compared 
between treatment groups using an ANCOVA40 model 
adjusting for baseline score and minimisation variables. 
Here a complete case approach was taken for missing data, 
so participants were included in the analysis only when 
they had both a baseline and 24 month score for the 
outcome measure being examined. Because these variables 
showed divergence from a normal distribution, non-
parametric, bias corrected and accelerated, bootstrap CIs 
were calculated from 2000 replications41 (boot strapping is a 
computer intensive technique that can give valid CIs even 
when normality assumptions do not hold42). A consequence 
of use of the bootstrap is that exact p values are not 
calculated: however, whether or not p<0·05 (or p<0·01) 
was inferred from the 95% (or 99%) CI. We compared 
incidence of new and enlarging T2 hyper-intense brain 
lesions and the relapse rate between treatment groups 
with an over-dispersed Poisson model,43 with adjustment 
for minimisation variables and adjustment for MRI site 
where relevant. All available data were used for analysis of 
relapse rates and new and enlarging lesions, with 
participants included in the analysis if they had information 
recorded on at least one follow-up assessment.
Percentage expression of FoxP3 on CD4+ T cells and 
inducible levels (unstimulated subtracted from the 
stimulated value) of IFN-γ, IL-4, IL-10 and IL-17 on all 
CD3+ T cells were calculated after suitable transformation 
(natural logarithm or square root). Linear mixed models 
were used to compare the mean value of each marker 
between the placebo and simvastatin group at 6, 12, and 
24 months, with adjustment for minimisation variables. 
To make this analysis essentially equivalent to an 
ANCOVA,44 adjusting for baseline, measures of the 
marker at baseline were treated as an additional outcome 
in the model with treatment eﬀ ects and eﬀ ects of 
minimisation variables constrained to be zero at 
baseline.44 This approach allows use of all available 
measures of the marker for each participant to be 
included in the analysis.
Safety was examined by testing the null hypothesis that 
there was no increase in the proportion of participants 
with at least one serious adverse event in the active 
compared with the placebo group, with a one-sided test.
Role of the funding source
None of the funding sources were involved in the 
analysis, writing, or decision to submit the manuscript. 
Placebo (n=70) Simvastatin 
(n=70)
Diﬀ erence 
in means*
95% CI for 
diﬀ erence
Change in whole-brain volume (% per year)*†
Mean (SD) rate 0·584 (0·498) 0·288 (0·521) –0·254‡ −0·422 to −0·087
Number (%) assessed 64 (91%) 66 (94%) ·· ··
Number of BBSI measures 165 175 ·· ··
EDSS (score 0 to 10)
Mean (SD) at 24 months 6·35 (0·83) 5·93 (1·11) –0·254§ −0·464 to −0·069
Number (%) assessed 61 (87%) 67 (96%) ·· ··
MSIS-29 total (score 29 to 116)
Mean (SD) at 24 months 76·1 (16·3) 70·1 (15·6) –4·78¶ −9·39 to −0·02
Number (%) assessed 57 (81%) 66 (94%) ·· ··
MSIS-29 physical (score 20 to 80)
Mean (SD) at 24 months 56·3 (11·8) 51·7 (11·4) –3·73¶ −7·18 to −0·28
Number (%) assessed 57 (81%) 66 (94%) ·· ··
MSIS-29 psychological (score 9 to 36)
Mean (SD) at 24 months 19·8 (6·0) 18·3 (5·8) −1·09 −2·83 to 0·84
Number (%) assessed 57 (81%) 66 (94%) ·· ··
MSFC Z score
Mean (SD) at 24 months −1·21 (2·59) −0·78 (2·06) 0·289 −0·333 to 0·961
Number (%) assessed 49 (70%) 58 (83%) ·· ··
MSFC walk (speed ft per s)
Mean (SD) at 24 months 1·55 (1·19) 1·83 (1·61) 0·085 −0·249 to 0·533
Number (%) assessed 54 (77%) 62 (89%) ·· ··
MSFC peg test (speed per s)
Mean (SD) at 24 months 0·030 (0·014) 0·033 (0·010) 0·002 −0·001 to 0·004
Number (%) assessed 54 (77%) 61 (87%) ·· ··
MSFC PASAT (score 0 to 60)
Mean (SD) at 24 months 35·2 (18·0) 38·3 (15·4) 4·45 −0·11 to 8·84
Number (%) assessed 50 (71%) 61 (87%) ·· ··
BBSI=brain boundary shift integral. EDSS=Kurtzke expanded disability status scale. MSFC=multiple sclerosis functional 
composite. MSIS=multiple sclerosis impact scale. PASAT=paced auditory serial addition test. *Adjusted for 
minimisation variables and MRI site for change in whole-brain volume; adjusted for minimisation variables and 
baseline measurement of outcome for all other outcomes. †Positive values reﬂ ect decrease in brain volume. ‡p=0·003. 
§p<0·01. ¶p<0·05. All CIs, other than that for the comparison of atrophy rates, are bias-corrected and accelerated 
non-parametric bootstrap conﬁ dence computed from 2000 bootstrap samples.
 Table 2: Changes in whole-brain volume between 0, 12, and 25 months and secondary clinical outcomes 
at 24 months
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There has been no pharmaceutical company involvement 
in this study. The corresponding author has had full 
access to all the data in the study and takes ﬁ nal 
responsibility to submit for publication.
Results
Figure 1 shows the trial proﬁ le. 140 participants were 
randomly assigned to receive either simvastatin (n=70) or 
placebo (n=70). The two groups were very similar on 
baseline variables used for minimisation and for most 
other baseline variables, including whole-brain volume 
(table 1). A slightly higher proportion of the simvastatin 
group was white and a lower proportion had experienced a 
relapse in the last 12 or 24 months. Nine participants were 
lost to follow-up (six in the placebo group and three in the 
treatment group). Of the patients who completed follow-
up, compliance was at least 90% for 49 patients (77%) for 
placebo and 52 patients (78%) for simvastatin. Cholesterol 
was signiﬁ cantly reduced from mean 5·5 (SD 1·1) 
mmol/L at baseline to 4·1 (0·9) mmol/L at 24 months in 
the simvastatin group (p<0·0001), whereas it did not 
change in the placebo group from 5·6 (0·9) mmol/L at 
baseline to 5·6 (1·0) mmol/L at 24 months (p=0·93).
In the prespeciﬁ ed intention-to-treat analysis mean 
atrophy rate was lower in the simvastatin group at 
0·288% (SD 0·521) per year than in the placebo group at 
0·584% (0·498) per year. The adjusted diﬀ erence in 
atrophy rate between the groups was −0·254% per year 
(95% CI −0·422 to −0·087; p=0·003), which is a 43% 
reduction in annualised rate of atrophy (table 2). This 
reduction in annualised rate of atrophy is readily 
apparent when examining the individual patient values 
(ﬁ gure 2); between 0 and 25 months more than three-
quarters of patients in the simvastatin group had a lower 
atrophy rate than the mean rate in the placebo group. 
There was a similar reduction in the simple mean 
atrophy rate between baseline and 25 months, which was 
likewise lower in the simvastatin group at 0·294% 
(0·508) per year versus the placebo group at 0·565% 
(0·473) per year (ﬁ gure 2). Between baseline and 
Figure 2: Primary MRI outcome and secondary clinical outcomes
The mean and individual patient values are shown for change in whole-brain volume (A); percentage of patients with a given change in EDSS (B); change 0 to 
24 months MSIS-29 (C); and change 0 to 24 months MSFC (D). For panels A, C, and D the mean is indicated by solid bar, placebo group by dark blue points, and 
simvastatin group by pale blue points. For change in whole-brain volume, EDSS, and MSIS-29, a positive value indicates a worse outcome. A positive value for MSFC 
Z score indicates an improved outcome. BSI=brain boundary shift integral. WBV=whole-brain volume. EDSS=Kurtzke expanded disability status scale. MSIS=multiple 
sclerosis impact scale. MSFC=multiple sclerosis functional composite.
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12 months, mean rates were similar to those observed 
between 0 and 25 months, but as expected variability was 
greater (simvastatin group 0·375% [0·631] per year 
versus placebo group 0·597% [0·617] per year). The 
results from the per-protocol analysis of all measured 
changes were very similar to those found for the 
intention-to-treat analysis. The mean atrophy rate was 
lower in the simvastatin group (0·298% [SD 0·562] per 
year) than in the placebo group (0·589% [0·528] per 
year), with adjusted diﬀ erence of −0·279% per year 
(95% CI −0·488 to −0·071; p=0·009).
At 24 months we recorded a statistically signiﬁ cant 
diﬀ erence in favour of simvastatin versus placebo for 
EDSS (diﬀ erence −0·254; 95% CI −0·464 to −0·069; 
p<0·01) and total MSIS-29 (−4·78; 95% CI −9·39 to 
−0·02; p<0·05), in particular the MSIS-29 physical 
subscale (−3·73; −7·18 to −0·28; p<0·05), with a trend in 
the MSIS-29 psychological outcome that did not reach 
formal statistical signiﬁ cance (−1·09; −2·83 to 0·84; 
p>0·10; table 2). In the MSFC there was no signiﬁ cant 
diﬀ erence between the sim vastatin and placebo groups, 
though those on simvastatin had a slightly more 
favourable MSFC than placebo (0·289; 95% CI −0·333 
to 0·961; p>0·10). Changes in score between baseline 
and 24 months for most secondary outcomes generally 
reﬂ ected worsening over time, particularly in the placebo 
group (ﬁ gure 2). There was no signiﬁ cant diﬀ erence 
between the simvastatin and placebo group in the rate of 
new and enlarging lesions (incidence rate ratio 0·72; 
95% CI 0·45 to 1·16; p=0·176) or in the rate of relapse 
(1·29; 0·64 to 2·60; p=0·473; table 3). Results for the per-
protocol analyses were similar to those for the intention-
to-treat analyses for all secondary outcomes, including 
Placebo Simvastatin Incidence rate 
ratio*
95% CI p value
New and enlarging T2 lesions
Rate per person-year (N events) 2·19 (283) 1·50 (205) 0·72 0·45–1·16 0·176
Number (%) of patients assessed 63 (90%) 65 (93%) ·· ·· ··
Relapses
Rate per person-year (N events) 0·16 (22) 0·20 (28) 1·29 0·64–2·60 0·473
Number (%) of patients assessed 70 (100%) 70 (100%) ·· ·· ··
*Adjusted for minimisation variables and MRI site for new and enlarging T2 lesions; adjusted for minimisation variables 
for relapse rate.
Table 3: Rate of new and enlarging T2 lesions between over 0 to 25 months and relapse rate over 0 to 
24 months Placebo 
(n=70)
Simvastatin 
(n=70)
Number with any adverse event 54 (77%) 49 (70%)
Cause of most common adverse events (>10% per group)
Relapse 17 (24%) 17 (24%)
Cramp 10 (14%) 12 (17%)
Headache 10 (14%) 3 (4%)
Pain 13 (19%) 7 (10%)
Worsening mobility 8 (11%) 9 (13%)
Increased spasticity 7 (10%) 0 (0%)
Urinary tract infection 8 (11%) 9 (13%)
Number with drug-related adverse event 13 (19%) 16 (23%)
Number with serious adverse event 14 (20%) 9 (13%)
Cause of serious adverse event
Grade 3 relapse* 5 (7%) 3 (4%)
Abdominal lesion biopsy 1 (1%) 0 (0%)
Appendectomy 1 (1%) 0 (0%)
Depression 0 (0%) 1 (1%)
Fall 1 (1%) 0 (0%)
Fracture 2 (3%) 1 (1%)
Pneumonia 0 (0%) 1 (1%)
Pulmonary embolism 1 (1%) 0 (0%)
Road traﬃ  c accident 1 (1%) 0 (0%)
Seizures 0 (0%) 2 (3%)
Increased spasticity 1 (1%) 0 (0%)
Sub-arachnoid haemorrhage 1 (1%) 0 (0%)
Urinary tract infection 3 (4%) 2 (3%)
Upper respiratory tract infection 0 (0%) 2 (3%)
Viral encephalitis 0 (0%) 1 (1%)
Data are number (%).*Relapse needing hospital admission.
 Table 4: Adverse events
Figure 3: Mean and 95% CI for the diﬀ erence between simvastatin and placebo groups in immunological 
markers at 6, 12, and 24 months
The diﬀ erence between simvastatin and placebo in inducible levels of cytokine expression is shown for square root 
IFNγ (A), natural log IL-4 (B), natural log IL-10 (C), and natural log IL-17 (D). The diﬀ erence between simvastatin 
and placebo is shown for natural log of % CD4 Fox P3 expression (E). Analyses of each marker included at least 
134 participants, with number at each timepoint between 91 participants (IL-17 at 24 months) and 
112 participants (IL-10 at 6 months). Means and 95% CIs are adjusted for minimisation variables and baseline 
measurement of the marker. The dashed line indicates zero diﬀ erence between groups.
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clinical outcomes, incidence of relapse, and incidence of 
new and enlarging lesions.
We noted no signiﬁ cant diﬀ erences between the 
simvastatin and placebo groups for inducible levels of 
IFN-γ, IL-4, IL-10, and IL-17 expression on T cells at any 
timepoint. No signiﬁ cant diﬀ erences were noted at any 
timepoint between the placebo and simvastatin-treated 
groups in expression of FoxP3 on the CD4+ T cells 
(ﬁ gure 3).
Of the 70 participants in the placebo group, 54 (77%) had 
one or more adverse events, with 14 (20%) partici pants 
having a serious adverse event. In the simvastatin group, 
49 (70%) of 70 participants had an adverse event, and nine 
(13%) had a serious adverse event. There was no evidence 
that a greater proportion of participants in the simvastatin 
group had adverse events during the trial, compared with 
the placebo group (p=0·873, one-sided for serious adverse 
events; p=0·831, one-sided for any adverse event; table 4). 
The treatment was therefore well tolerated with no safety 
diﬀ erences between the two groups.
Discussion
Our ﬁ ndings show that, compared with placebo, 
simvastatin 80 mg per day reduced the annualised rate of 
whole-brain atrophy by 43%. To minimise the possibility 
that unknown changes in imaging volumes could take 
place (such as pseudo-atrophy), both the initial and ﬁ nal 
MR imaging were done oﬀ -medication. This technique 
supports the contention that the noted reduction was due 
to a real eﬀ ect on ongoing disease-related progression 
(disease-modifying or neuroprotective), rather than to an 
indirect and short-term eﬀ ect of drug presence (eg, 
on hydration). Furthermore, diﬀ erences between the 
two groups were consistently seen over 0–12 months, 
12–25 months, and 0–25 months. Moreover, the rate of 
atrophy in the placebo group was very similar to the 0·64% 
per year reported in a study of more than 130 patients with 
untreated secondary progressive multiple sclerosis.45
This eﬀ ect on brain atrophy rate is positive, given that 
longitudinal studies have shown a relation between 
atrophy progression and disability.46 Nonetheless, caution 
should be taken regarding overinterpretation of brain 
imaging ﬁ ndings, because these might not necessarily 
translate into clinical beneﬁ t. We also noted a small, but 
signiﬁ cant, eﬀ ect in two of the secondary disability 
outcomes, as assessed from a physician (EDSS) and 
patient reported (MSIS-29) viewpoint supporting a true 
eﬀ ect on disease progression. However, because the study 
was phase 2, it was not designed to assess the proportions 
with conﬁ rmed EDSS progression. Although the EDSS is 
a clinically relevant score with well described limit ations,47 
it remains the favoured outcome of regulators for trials,48 
and to discern an eﬀ ect is encouraging. Simvastatin 
showed no eﬀ ect on relapse frequency, but there was a 
non-signiﬁ cant reduction in T2 lesion accumulation, as 
recorded in some trials of early multiple sclerosis.17,18 This 
study was done in a typical secondary progressive multiple 
sclerosis cohort6,7,44 and supports a biologically plausible 
relation between MRI-derived whole-brain atrophy rate 
and disability measures, in secondary progressive multiple 
sclerosis, as proposed by international expert groups on 
neuroprotection in multiple sclerosis.48,49
Seven randomised controlled trials have been done in 
early stage multiple sclerosis, using simvastatin and 
atorvastatin (panel). The relapsing-remitting multiple 
sclerosis studies, as add-on to β-interferon, showed in 
totality, neither harm nor beneﬁ t on parameters such as 
relapse rate or MRI measures.21,50,51 No emergent safety 
issues were identiﬁ ed. In clinically isolated syndrome the 
STAyCIS study with atorvastatin, although not meeting 
the primary endpoint (≥3 new T2 lesions or ≥1 relapse), 
did signiﬁ cantly reduce the proportion with new 
T2 lesions by 50%.52 A study of simvastatin in patients 
with optic neuritis followed-up for 6 months, showed a 
borderline beneﬁ t on contrast sensitivity and signiﬁ cant 
eﬀ ects on several other visual secondary outcomes.53
The failure to show a robust eﬀ ect on the inﬂ ammatory 
component of early stage multiple sclerosis could be 
explained by insuﬃ  cient power. The largest study 
SIMCOMBIN (n=307) achieved 65% rather than 80% 
power for the primary endpoint.18 Other contributory 
reasons could be that statins might not possess the 
eﬀ ective and sustained immunomodulatory properties 
seen in earlier experimental studies at the dosing 
schedules used in human trials. Indeed, we did not note 
any eﬀ ects of simvastatin on the immune markers tested. 
Reasons, apart from possible insuﬃ  cient power, might be 
drug tolerance (induction of long-term compensatory 
mechanisms acting before the 6 month assay timepoint), 
or that the in-vivo statin concentration was lower than that 
achieved in vitro. The mechanism by which brain 
penetrant simvastatin causes a signiﬁ cant reduction in the 
annualised rate of whole-brain atrophy and the 
improvement in two major disability outcomes in this 
Panel: Research in context
Systematic review
We searched for all studies in Medline (from 1946), Embase (from 1980), PubMed, Cochrane 
Database of Systematic Reviews, CENTRAL, DARE, and the Health Technology Assessment 
Database up (from 2013) to April, 2013, using the keywords: “multiple sclerosis” AND 
“statins”. We included trials, observational studies, and laboratory studies in humans and 
animals. The book of abstracts from the meetings of the European Committee for Treatment 
and Research in Multiple Sclerosis for the previous 8 years was also searched. The resulting 
papers were examined manually. This search yielded seven randomised controlled trials: one 
in clinically-isolated syndrome, one in optic neuritis, ﬁ ve in relapsing-remitting multiple 
sclerosis, and none in secondary progressive multiple sclerosis.
Interpretation
This phase 2 study of statins in secondary progressive multiple sclerosis showed that 
simvastatin at 80 mg a day was safe, well tolerated, and reduced progression of annualised 
brain atrophy over 2 years. Simvastatin had small but signiﬁ cant eﬀ ects on two of the 
secondary clinical outcomes. The mechanism of action needs to be established, but might be 
due to an eﬀ ect on vascular function or cell protection.
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study therefore remains to be elucidated. Accumulating 
evidence shows that statins have cell protective properties.10 
For example, inhibition of inducible nitric oxide synthase, 
thus reducing release of free radicals from activated 
microglia and astrocytes13 or exerting a neuroprotective 
eﬀ ect by prevent ion of glutamate-mediated excitotoxic 
eﬀ ects.54 An alternative or additional mechanism could be 
through an eﬀ ect on vascular function.16 Statins acting 
through endothelial nitric oxide synthase55 can result in 
improved cerebral vasomotor reactivity14,56 protecting 
against long-term hypoxic damage.57 Finally, since vascular 
comorbidity is associated with a substantial risk of 
disability in multiple sclerosis,58 the noted beneﬁ t might 
be directly due to the reduction in total cholesterol 
achieved in this study.
In summary, our results show that oral simvastatin at 
80 mg per day might be a treatment option for secondary 
progressive multiple sclerosis, which is currently 
untreatable, and warrants further investigation in a 
larger phase 3 trial.
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